CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
aqueous subcutaneous progesteronedrug
Likely dose
aqueous subcutaneous progesterone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04665232
NCT04665232N/ACompleted
CompareCT.gov

Immunomodulatory Effects of Subcutaneous Progesterone in Patients Undergoing IVF Affected by Autoimmune Diseases

San Carlo Public Hospital, Potenza, Italy·observational·Posted Dec 11, 2020·Updated May 28, 2024

In Brief

An observational study evaluating aqueous subcutaneous progesterone for Autoimmune Diseases and Infertility. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This study evaluates the immunomodulatory effects of subcutaneous progesterone in patients undergoing IVF by determination of anti-nuclear antibodies (ANA),extractable nuclear antigen antibodies (ENA),anti- neutrophil cytoplasmic antibodies(ANCA),anti-DNA antibodies, anti-cardiolipin antibodies (ACA),Lupus anticoagulant antibodies (LAC) and C3 and C4 fractions of complement on the day of beta hCG dosage and during the eigth week of gestation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Diseases, Infertility
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 11, 2020
Enrollment StartApr 1, 2014
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 5.6 years ago

Interventions

aqueous subcutaneous progesteronedrug

25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.